These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

819 related items for PubMed ID: 17026489

  • 1. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
    Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H, Garber A.
    Diabetes Obes Metab; 2006 Nov; 8(6):650-60. PubMed ID: 17026489
    [Abstract] [Full Text] [Related]

  • 2. Improvement in glycaemic control with rosiglitazone/metformin fixed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic control.
    Rosenstock J, Rood J, Cobitz A, Huang C, Garber A.
    Diabetes Obes Metab; 2006 Nov; 8(6):643-9. PubMed ID: 17026488
    [Abstract] [Full Text] [Related]

  • 3. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.
    Bailey CJ, Bagdonas A, Rubes J, McMorn SO, Donaldson J, Biswas N, Stewart MW.
    Clin Ther; 2005 Oct; 27(10):1548-61. PubMed ID: 16330291
    [Abstract] [Full Text] [Related]

  • 4. Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes.
    Chou HS, Palmer JP, Jones AR, Waterhouse B, Ferreira-Cornwell C, Krebs J, Goldstein BJ.
    Diabetes Obes Metab; 2008 Aug; 10(8):626-37. PubMed ID: 17645558
    [Abstract] [Full Text] [Related]

  • 5. Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.
    Hamann A, Garcia-Puig J, Paul G, Donaldson J, Stewart M.
    Exp Clin Endocrinol Diabetes; 2008 Jan; 116(1):6-13. PubMed ID: 18095238
    [Abstract] [Full Text] [Related]

  • 6. A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.
    Davidson JA, McMorn SO, Waterhouse BR, Cobitz AR.
    Clin Ther; 2007 Sep; 29(9):1900-14. PubMed ID: 18035190
    [Abstract] [Full Text] [Related]

  • 7. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
    Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.
    Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
    [Abstract] [Full Text] [Related]

  • 8. Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes.
    Rosenstock J, Chou HS, Matthaei S, Seidel DK, Hamann A.
    Diabetes Obes Metab; 2008 Sep; 10(10):862-73. PubMed ID: 18201206
    [Abstract] [Full Text] [Related]

  • 9. Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study.
    Goldstein BJ, Weissman PN, Wooddell MJ, Waterhouse BR, Cobitz AR.
    Curr Med Res Opin; 2006 Sep; 22(9):1715-23. PubMed ID: 16968575
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of avandamet or uptitrated metformin treatment in patients with type 2 diabetes inadequately controlled with metformin alone: a multicenter, randomized, controlled trial.
    Cai XL, Chen YL, Zhao JJ, Shan ZY, Qiu MC, Li CJ, Gu W, Tian HM, Yang HZ, Xue YM, Yang JK, Hong TP, Ji LN.
    Chin Med J (Engl); 2015 May 20; 128(10):1279-87. PubMed ID: 25963345
    [Abstract] [Full Text] [Related]

  • 11. A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naïve type 2 diabetes mellitus patients.
    Borges JL, Bilezikian JP, Jones-Leone AR, Acusta AP, Ambery PD, Nino AJ, Grosse M, Fitzpatrick LA, Cobitz AR.
    Diabetes Obes Metab; 2011 Nov 20; 13(11):1036-46. PubMed ID: 21682834
    [Abstract] [Full Text] [Related]

  • 12. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.
    Kadoglou NP, Kapelouzou A, Tsanikidis H, Vitta I, Liapis CD, Sailer N.
    Exp Clin Endocrinol Diabetes; 2011 Feb 20; 119(2):63-8. PubMed ID: 21031343
    [Abstract] [Full Text] [Related]

  • 13. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
    Wainstein J, Katz L, Engel SS, Xu L, Golm GT, Hussain S, O'Neill EA, Kaufman KD, Goldstein BJ.
    Diabetes Obes Metab; 2012 May 20; 14(5):409-18. PubMed ID: 22059736
    [Abstract] [Full Text] [Related]

  • 14. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
    Fonseca V, Rosenstock J, Patwardhan R, Salzman A.
    JAMA; 2000 Apr 05; 283(13):1695-702. PubMed ID: 10755495
    [Abstract] [Full Text] [Related]

  • 15. Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study.
    Weissman P, Goldstein BJ, Rosenstock J, Waterhouse B, Cobitz AR, Wooddell MJ, Strow LJ.
    Curr Med Res Opin; 2005 Dec 05; 21(12):2029-35. PubMed ID: 16368054
    [Abstract] [Full Text] [Related]

  • 16. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study.
    Rosenstock J, Goldstein BJ, Vinik AI, O'neill MC, Porter LE, Heise MA, Kravitz B, Dirani RG, Freed MI, RESULT Study Group.
    Diabetes Obes Metab; 2006 Jan 05; 8(1):49-57. PubMed ID: 16367882
    [Abstract] [Full Text] [Related]

  • 17. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes.
    Jones TA, Sautter M, Van Gaal LF, Jones NP.
    Diabetes Obes Metab; 2003 May 05; 5(3):163-70. PubMed ID: 12681023
    [Abstract] [Full Text] [Related]

  • 18. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.
    J Clin Pharm Ther; 2006 Aug 05; 31(4):375-83. PubMed ID: 16882108
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.
    Yoon KH, Steinberg H, Teng R, Golm GT, Lee M, O'Neill EA, Kaufman KD, Goldstein BJ.
    Diabetes Obes Metab; 2012 Aug 05; 14(8):745-52. PubMed ID: 22405352
    [Abstract] [Full Text] [Related]

  • 20. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.
    Patel J, Anderson RJ, Rappaport EB.
    Diabetes Obes Metab; 1999 May 05; 1(3):165-72. PubMed ID: 11220295
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.